CD19 and graft versus host disease: To increase the GVL effect without causing any GVHD, a phase 2 trial (NCT03849651) is being conducted where TCRαβ- and CD19-depleted graft infusions are followed by CD45RA-depleted DLI at least two weeks after engraftment.